Session Information
Date: Wednesday, June 22, 2016
Session Title: Cognitive disorders
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: Evaluate the relationship between magnetic resonance (MRI) abnormalities and neuropsychological assessment in Parkinson s disease mild cognitive impairment (PD-MCI) and controls with mild cognitive impairment (CO-MCI).
Background: The recognition and treatment of cognitive impairment are increasingly emphasized in the care of PD. PD-MCI is one of the most important risk factor related to dementia. Global Cerebral Atrophy (CGA), Medial Temporal Atrophy (MTA) and white matter hyperintensities could be found more frequently in Parkinson s disease dementia. We evaluated if these structural changes could be related with neuropsychological pattern of PD-MCI comparing with CO-MCI.
Methods: 75 PD and 88 controls (CO) were evaluated, 50 PD and 61 CO were excluded because didn t have MRI scan, presented one or more findings that could be related to cognitive impairment (use of benzodiazepine or anticholinergic, MRI or blood abnormalities) or fulfilled criteria for dementia or depression. The assessment consists of: neurology examination, Hoehn-Yahr, UPDRS, PDQ 39, Schwab-England, Beck scale, L-dopa dose, neuropsychological battery, Global Cerebral Atrophy (GCA), medial temporal atrophy (MTA), Evans Index, and Fazekas scale (FS).
Results: Both groups were classified by neuropsychological assessment in amnestic or non- amnestic. No differences were observed on several demographic data.
Variables | DP Amnestic MCI n=13 mean (sd) | DP Nonamnestic MCI n=12 mean (sd) | Control Amnestic MCI n=18 mean (sd) | Control Nonamnestic MCI n=9 mean (sd) | p-value |
Age (years) | 60.23 (7.132) | 58.92 (6.908) | 60.72 (6.323) | 60.89 (6,451) | 0.781 (a) |
Education Level (years) | 9.23 (4.126) | 10.25 (2.864) | 12.72 (3.893) | 13.22 (4.147) | 0.031(a) |
Sex % (male / female) | 53.8 / 46.2 | 83.3 / 16.7 | 27.8 / 72.2 | 11.1 / 88.9 | |
MMSE | 27.31 (1.601) | 27.83 (1.337) | 27.89 (1.278) | 27.89 (1.269) | 0.651(a) |
MoCA | 23.00 (2.915) | 24.00 (3.191) | 22.94 (2.754) | 23.89 (3.180) | 0.710(a) |
BDI | 8.38 (5.591) | 5.33 (4.438) | 7.50 (5.159) | 8.22 (3.232) | 0.404(a) |
Years since diagnosis (months) | 64.62 (31.574) | 68.00 (37.717) | – | – | 0.809(b) |
Levodopa dosage equivalence (Mg) | 636.31 (292.665) | 1783.75 (4060.456) | – | – | 0.350(b) |
UPDRS-III | 18.54 (9.421) | 15.92 (5.791) | – | – | 0.088(b) |
PDQ39 (total) | 28.50 (14.112) | 19.55 (10.914) | – | – | 0.408(b) |
Schwab-England | 83.08 (7.511) | 88.33 (3.892) | – | – | 0.039(b) |
Cerebrovascular risk factor % | 38.5 | 25.0 | 38.9 | 66.7 | |
Smoking % (sim / não) | 38.5 / 61.5 | 83.3 / 16.7 | 5.6 / 94.4 | 11.1 / 88.9 | |
Global Cerebral Atrophy % (score 0/1/2/3) | 46.2 / 46.2 / 7.7/0.0 | 50.0 / 50.0 / 0.0/0.0 | 33.3 / 44.4 / 5.6/0.0 | 55.6 / 44.4 / 0.0/0.0 | |
MTA % (score 0/1/2/3/4) | 46.2 / 46.2 / 7.7/0.0/0.0 | 58.3 / 41.7 / 0.0/0.0/0.0 | 61.1 / 33.3 / 5.6/0.0/0.0 | 55.6 / 44.4 / 0.0/0.0/0.0 | |
FAZEKAS % (score 0/1/2/3) | 38.5 / 46.2 / 7.7 / 7.7 | 58.3 / 25.0 / 8.3 / 8.3 | 38.9 / 38.9 / 11.1 / 55.6 | 11.1 / 55.6 / 33.3 / 0.0 | |
(a) One-way ANOVA; (b) t-test |
Neuropsychological Tests | DP Amnestic MCI n=13 mean (sd) | DP Nonamnestic MCI n=12 mean (sd) | p-value (a) | Control Amnestic MCI n=18 mean (sd) | Control Nonamnestic MCI n=9 mean (sd) | p-value(a) | PS | ||||||
MI(b;1) | 5.08 (1.038) | 6.50 (1.508) | 0.013 | 5.33 (1.188) | 5.78 (1.202) | 0.377 | Storage of information that occurs passively (i.e., without conscious effort). MEMORY | ||||||
M1(b;2) | 6.92 (1.320) | 8.25 (1.055) | 0.011 | 8.11 (1.023) | 8.78 (1.302) | 0.202 | Visual short-term memory MEMORY | ||||||
M2(b;3) | 8.92 (0.862) | 9.25 (0.754) | 0,323 | 8.56 (1.542) | 9.67 (0.500) | 0.011 | Visual learning MEMORY | ||||||
M5(b;4) | 7.00 (2.345) | 8.75 (0.754) | 0.022 | 8.39 (1.243) | 8.89 (1.054) | 0.288 | Visual long-term memory MEMORY | ||||||
A6(c;6) | 3.85 (2.410) | 8.75 (2.491) | < 0.001 | 7.22 (3.135) | 9.78 (3.153) | 0.064 | Verbal memory MEMORY | ||||||
A7(c;7) | 4.00 (2.121) | 9.25 (2.417) | < 0.001 | 7.00 (3.881) | 10.56 (3.005) | 0.016 | Verbal long-term memory MEMORY | ||||||
LOT(c;8) | 11.54 (5.487) | 21.33 (7.228) | 0.001 | 17.67 (8.260) | 20.33 (6.124) | 0.355 | Verbal learning MEMORY | ||||||
RI(c;9) | 0.49 (0.275) | 0.76 (0.203) | 0.010 | 0,75 (0.286) | 0.83 (0.132) | 0.343 | Interference MEMORY and EXECUTIVE FUNCTIONS | ||||||
Recognition(c;10) | 4.62 (4.053) | 11.08 (2.811) | < 0.001 | 6.28 (4.417) | 12.33 (2.646) | < 0.001 | Recognition memory MEMORY | ||||||
TMT A(d) | 71.83 (18.914) | 68.06 (18.895) | 0.641 | 53.39 (17.431) | 40.13 (9.040) | 0.017 | Processing Speed EXECUTIVE FUNCTIONS | ||||||
FAS(f) | 25.62 (6.449) | 35.08 (8.458) | 0.005 | 31.83 (7.710) | 33.22 (5.191) | 0.585 | Phonemic verbal fluency EXECUTIVE FUNCTIONS | ||||||
(a)t-Test; (b)Figures Memory Test – Nitrini (1994); (1)MI = incidental memory; (2)M1= number of figures recalled after 1-minute visualization;(3)M2= Learning; (4)M5= recall of memorized figures after 5 minutes; (c)Rey Auditory Verbal Learning Test – Malloy-Diniz (2007); (5)B1=retrieval of words included in the interference list of 15 new substantives; (6)A6= number of words memorized from list A without reread; (7)A7 = number of words memorized from list A, without reread, after 20-minute interval; (8)LOT=leaning curve of the wordsduring attempts A1 to A5; (9)RI= Retroactive Interference (A6/A5); (10)correct answers in recognitive list; (d)TMT A = trail making test – trail A (time in seconds); (e)FVS=semantic verbal fluency (animals); (f)FAS=phonemic verbal fluency (letters F, A and S) |
Conclusions: Structural abnormalities in MRI were more common in PD-MCI than MCI-CO. PD group presented more prominent impairment than control. MRI could be more useful in PD-MCI than MCI-CO and could reflect irreversible structural changes beyond basal ganglia in PD. Burton EJ, McKeith IG, Burn DJ et al. Cerebral atrophy in Parkinson s disease with and without dementia. Brain. 2004;127:791-800. Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Parkinson s disease. Age Ageing. 2013;42(5):567-76.
To cite this abstract in AMA style:
L.F.R. Vasconcellos, M. Adachi, D. Greca, M. Cruz, A.L. Malak, H. Charchat-Fichman, J.S. Pereira. Neuropsychology and magnetic resonance correlation in Parkinson´s disease mild cognitive impairment: Case-control study [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/neuropsychology-and-magnetic-resonance-correlation-in-parkinsons-disease-mild-cognitive-impairment-case-control-study/. Accessed September 7, 2024.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/neuropsychology-and-magnetic-resonance-correlation-in-parkinsons-disease-mild-cognitive-impairment-case-control-study/